NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-21-127 from the NIH Guide for Grants and Contracts. The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-priced, specialized, commercially available instruments or integrated instrumentation system. The minimum award is $50,000. There is no maximum price limit for the instrument; however, the maximum award is $600,000. Instruments supported include, but are not limited to: X-ray diffractometers, mass spectrometers, nuclear magnetic resonance spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, cell sorters, and biomedical imagers.
Funding Opportunity PAR-21-126 from the NIH Guide for Grants and Contracts. The High-End Instrumentation (HEI) Grant program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-end, specialized, commercially available instruments or integrated systems. The minimum award is $600,001. There is no maximum price limit for the instrument; however, the maximum award is $2,000,000. Instruments supported include, but are not limited to, biomedical imagers, high throughput robotic screening systems, X-ray diffractometers, mass spectrometers, nuclear magnetic resonance (NMR) spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, and cell sorters.
Funding Opportunity PAR-21-125 from the NIH Guide for Grants and Contracts. The Basic Instrumentation Grant (BIG) Program encourages applications from groups of NIH-supported investigators to purchase a single high-priced, specialized, commercially available instrument or an integrated instrumentation system. The BIG Program is limited to institutions that have not received substantial S10 instrumentation awards of a total of $250,001 or greater in any of Federal fiscal years 2018-2020. The minimum award is $25,000. There is no maximum price limit for the instrument; however, the maximum award is $250,000. Instruments supported include, but are not limited to, basic cell sorters, confocal microscopes, ultramicrotomes, gel imagers, or computer systems.
Funding Opportunity PAR-21-115 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening. By defining the sequence and timing of the onset of symptoms and complications of a disorder, a valuable resource will be developed for the field. In addition, for some disorders, specific genotype-phenotype correlations may allow prediction of the clinical course, and for other disorders, identification of modifying genetic, epigenetic, or environmental factors will enhance an understanding of the clinical outcomes for an individual with such a condition. Comprehensive data on natural history will facilitate the field's ability to: 1) accurately diagnose the disorder; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the disorder; 3) identify underlying mechanisms related to basic defects; 4) potentially prevent, manage, and treat symptoms and complications of the disorder; and 5) provide children and their families with needed support and predictive information about the disorder.
Funding Opportunity PAR-21-060 from the NIH Guide for Grants and Contracts. The purpose of the NIDCR Predoctoral to Postdoctoral Transition Award for a Diverse Dental, Oral and Craniofacial Research Workforce (F99/K00) is to support outstanding graduate students from diverse backgrounds, including those from groups underrepresented in biomedical, clinical, behavioral and social sciences, over the transition from predoctoral to postdoctoral research training. This phased award program will facilitate completion of graduate PhD or dual degree clinician scientist programs (F99) and progression to mentored postdoctoral positions in dental, oral and craniofacial research (K00). It is anticipated that successful completion of this phased award program will enable achievement of an independent research faculty position and subsequent NIDCR career development and research project awards. This Funding Opportunity Announcement (FOA) does not allow prospective fellows to propose to lead an independent clinical trial, but does allow prospective fellows to propose research experience in a clinical trial led by a sponsor or co-sponsor.
Funding Opportunity RFA-AA-21-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be considered.
Funding Opportunity RFA-AA-21-002 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be considered. This RFA uses a three-year R01 mechanism
Funding Opportunity RFA-AA-21-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be considered.
Notice NOT-HS-21-008 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-034 from the NIH Guide for Grants and Contracts
Notice NOT-DA-21-017 from the NIH Guide for Grants and Contracts
Notice NOT-AI-21-008 from the NIH Guide for Grants and Contracts
Notice NOT-MD-21-012 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-060 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-054 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-22-006 from the NIH Guide for Grants and Contracts. This FOA will support high-throughput screening or similar transformative approaches to identify novel receptors, signal transducers, or small molecules that modulate SUD-relevant signal transduction pathways (dopamine, opioid, cannabinoid, nicotinic, or other appropriately justified pathway). These projects may also include secondary screens and/or validation of key hits identified.
Funding Opportunity RFA-AG-22-011 from the NIH Guide for Grants and Contracts. NIA invites applications for Phase 1, 2a, and 2b clinical trials of new compounds or re-purposed existing drugs, biologics (except stem cells), or supplements to treat multiple chronic conditions by modulating fundamental aging-related mechanisms as well as to test compounds that could affect the individual diseases and conditions disproportionally affecting older adults. This FOA is not intended to provide support for definitive efficacy and safety trials.
Notice NOT-DK-21-011 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-21-158 from the NIH Guide for Grants and Contracts. This FOA invites applications that propose research projects that test promising digital healthcare interventions aimed at improving quality of care and healthcare services delivery at the point of care. This FOA will use the Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities.
Funding Opportunity RFA-TR-21-009 from the NIH Guide for Grants and Contracts. This FOA is seeking applications for a portable sensing device to detect volatile organic compounds (VOCs, i.e. scents or odors) emanating from skin and to develop a catalog of VOCs as distinct signatures for at least 20 human diseases and conditions. These sensing devices must be able to associate VOC patterns using artificial intelligence to patients with various conditions for diagnostic purposes along with capabilities to incorporate and integrate vital signs. For VOC monitoring, these sensing devices can be Electronic-nose (E-nose) technology, Gas Chromatography (GC) or any sensing technology able to detect VOC patterns associated with disease. This new program is called SCENT, which stands for Screening for Conditions by E-Nose Technology. To ensure project success, this FOA requires multidisciplinary collaborations and a team science approach. Groups may include a combination of the following: Biomedical engineers, material scientists, biosensing experts, software engineers, chemists, clinicians, clinical trialists, biostatisticians, data analysts and/or other relevant experts in academia and industry.